Table 1.

Patient characteristics

CharacteristicNo. (%) of patients (n = 12)
Age, years
 Median70
 Range44–79
Sex
 Male9 (75%)
 Female3 (25%)
Disease type
 AML7 (58%)
 MM5 (42%)
AML characteristics
 FLT-3 ITD1
 TP53 mutation3
 FLT-3 TKD1
 Complex cytogenetics3
 Secondary AML4
Disease burden
 AML, marrow blasts (core), Median50%
  Range15%–60%
 AML, # with peripheral blasts4 (57%)
 AML, % peripheral blasts, Median8%
  Range0%–58%
 MM, marrow plasma cells, Range<5%–80%
 MM, FLC mg/dL, Median1,524
  Range0–2,615
 MM, serum M-protein, Median1.75 g/dL
  Range0–3.16 g/dL
 MM, urine M-protein, Median256 mg/24 h
  Range0–3969 mg/24 h
 MM, # with plasmacytomas3 (60%)
# Prior regimens
 AML, Median1
  Range0–4
 MMAll ≥5
 MM, prior ASCTAll ≥1
ALC, K/μL, Median0.58
 Range0.09–2.37
  • Abbreviations: ALC, absolute lymphocyte count; AML, acute myeloid leukemia; ASCT, autologous stem cell transplant; FLC, free light chain ratio; ITD, internal tandem duplication; MM, multiple myeloma; MDS, myelodysplastic syndrome; TKD, tyrosine kinase domain.